Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED [Gamma][Delta]-T CELLS FOR TREATMENT OF SOLID TUMORS

A technology of tumor cells and cells, which is applied on the surface of cells, including domains, can solve problems such as uncertainty

Pending Publication Date: 2021-08-17
APPLIED IMMUNE TECH LTD
View PDF25 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Notably, given the current lack of understanding of the costimulatory requirements of γδ T cells compared with αβ T cells, practical translation of any of these various approaches to γδ T cells is uncertain at best

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED [Gamma][Delta]-T CELLS FOR TREATMENT OF SOLID TUMORS
  • COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED [Gamma][Delta]-T CELLS FOR TREATMENT OF SOLID TUMORS
  • COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED [Gamma][Delta]-T CELLS FOR TREATMENT OF SOLID TUMORS

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0154] In the presence of IL-2 (100 U / mL), 1×10 6 / mL human PBMC were activated for 5 days in modified medium with anti-Vδ1 antibody D1-08 or D1-35 precoating. On day 5, cell cultures were transduced with a gamma-retroviral construct encoding an anti-TyrD chimeric antigen receptor (SEQ ID NO:8) in the presence of retronectin. On day 6, cells were returned to the modified medium and further expanded with feed and IL-2 replacement as needed. On day 17, 18 or 19, cells were harvested and used A kit (Miltenyi Biotec) was used to deplete remaining αβ T cells. Purity and transduction efficiency of γδ cell populations were assessed by FACS. In parallel, non-transduced cell cultures were expanded in the same manner without addition of retroviral supernatant. Such as figure 2 As shown, untransduced, expanded Vδ1 cells primed against cells known to express tyrosinase and present Tyr 369-377 Some degree of cytotoxicity of peptide 526 and WM266.1-Luc melanoma cell lines. This cyt...

Embodiment 2

[0156] WM266.4-Luc cells (4x10 6 individuals / animal) were subcutaneously implanted into NSG mice (Jackson Labs). When the tumor reaches 100-200mm 3 size, place the animal in a 6x10 6 An anti-TyrD CAR+Vδ1 cell therapy. Animals were concomitantly administered IL-2 (60,000 U / dose) 3 times a week throughout the study. result in image 3 described in . Such as image 3 As shown, animals administered anti-TyrD CAR+Vδ1 cells exhibited robust control of tumor burden.

Embodiment 3

[0158] The Tyr CAR construct was introduced into Vδ1 T cells as described above and the cells were expanded and tested in a cytotoxicity assay against WM266.4-Luc cells. A control, non-TyrD targeting CAR construct was used as a control. result in Figure 5 described and showed the increased cytotoxicity provided by anti-TyrD CAR constructs.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Aspects of the invention include compositions and methods for treatment of solid tumors with engineered or non-engineered [Gamma][Delta]-T cells. In some embodiments, the [Gamma][Delta]-T cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can contain an anti-TryD binding domain, a CD8alpha hinge and transmembrane domain, a costimulatory domain, a 003zeta signalling domain, a combination thereof, or all thereof. The CAR construct can contain an anti-GPC3 binding domain, a CD8alpha hinge and transmembrane domain, a costimulatory domain, a CD3zeta signalling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for a secreted common gamma chain cytokine such as a sIL 15 domain.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 739,826, filed October 1, 2018, the contents of which are hereby incorporated for any and all purposes. [0003] sequence listing [0004] This application contains a Sequence Listing, which was filed electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on January 8, 2020, is named ADC-0006-PCT_SL.txt and is 48,406 bytes in size. Background technique [0005] Adoptive cell therapy has undergone more than thirty (30 ) years of continuous iteration. While there have been hints and indications along the way of the healing potential of these approaches, much work remains to be done. In particular, whether CAR-T lymphocytes can successfully eradicate tumors depends on the persistence and effector functions of CAR-T cells, but an excess of either of these can trigger graf...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P35/00C07K16/28C07K16/30C07K19/00
CPCC07K16/2833C07K16/303C07K16/30C07K2317/622C07K2317/32C07K2317/73C07K2319/03C07K2319/33C07K2317/34A61P35/00C12N5/0636C12N2510/00A61K2239/53A61K39/464474A61K39/4611A61K39/4631A61K2239/57A61K2239/38A61K39/464456C07K14/70517C07K14/70521C07K14/70578C07K14/5443C12N15/62C07K2319/02C07K2317/565A61K2039/585A61K2121/00A61K2300/00A61K38/177A61K38/1774A61K38/2013A61K38/2086A61K39/39558A61K2039/505C07K14/7051C07K2317/74C07K2319/30
Inventor D.K.萨特帕耶夫M.A.赫尔曼J.M.罗梅罗Y.F.靖Z.安A.贾克博维茨
Owner APPLIED IMMUNE TECH LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com